These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 31147872)

  • 1. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
    Sattiraju A; Mintz A
    Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma Stem Cells and Their Microenvironment.
    Sattiraju A; Sai KKS; Mintz A
    Adv Exp Med Biol; 2017; 1041():119-140. PubMed ID: 29204831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes.
    Caspani EM; Crossley PH; Redondo-Garcia C; Martinez S
    PLoS One; 2014; 9(7):e101402. PubMed ID: 25032689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
    Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H
    Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.
    Persano L; Rampazzo E; Basso G; Viola G
    Biochem Pharmacol; 2013 Mar; 85(5):612-622. PubMed ID: 23063412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration.
    Uneda A; Kurozumi K; Fujimura A; Fujii K; Ishida J; Shimazu Y; Otani Y; Tomita Y; Hattori Y; Matsumoto Y; Tsuboi N; Makino K; Hirano S; Kamiya A; Date I
    Acta Neuropathol Commun; 2021 Feb; 9(1):29. PubMed ID: 33618763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
    Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.
    Shao R; Taylor SL; Oh DS; Schwartz LM
    Oncotarget; 2015 Dec; 6(38):40507-18. PubMed ID: 26439689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 12. Glioblastoma precision therapy: From the bench to the clinic.
    Zhou Y; Wu W; Bi H; Yang D; Zhang C
    Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.
    Fanelli GN; Grassini D; Ortenzi V; Pasqualetti F; Montemurro N; Perrini P; Naccarato AG; Scatena C
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma multiforme: novel therapeutic targets.
    Muir M; Gopakumar S; Traylor J; Lee S; Rao G
    Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The stem cell niche in glioblastoma: from fundamental aspects to targeted therapies].
    Turpin A; Sharif A; Stoven L; Blond S; Maurage CA; Le Rhun É
    Bull Cancer; 2015 Jan; 102(1):24-33. PubMed ID: 25609493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
    Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
    J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulated functional gene expression programmes in tumour pericytes mark progression in patients with low-grade glioma.
    Oudenaarden C; Sjölund J; Pietras K
    Mol Oncol; 2022 Jan; 16(2):405-421. PubMed ID: 34018679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
    Nigim F; Cavanaugh J; Patel AP; Curry WT; Esaki S; Kasper EM; Chi AS; Louis DN; Martuza RL; Rabkin SD; Wakimoto H
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):710-22. PubMed ID: 26083570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.